Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Ordered To Pay South Carolina $327 Million For "Detestable" Risperdal Marketing

This article was originally published in The Pink Sheet Daily

Executive Summary

The award is based on the number of drug samples distributed and Dear Doctor letters issued; South Carolina just filed a similar suit against GlaxoSmithkline over its Avandia marketing.

You may also be interested in...



J&J Says Penalties In Arkansas Risperdal Case ‘Excessive,’ Seeks New Trial

Argues that Arkansas Medicaid spent less than $10 million on Risperdal, but the fine imposed by a state judge for deceptive marketing practices would exceed $1.2 billion.

Risperdal Jury “Blown Away” By Testimony On Study Manipulation; J&J Settles Texas Suit

In the midst of a trial, Johnson & Johnson agrees to pay $158 million to settle a suit by the state of Texas alleging the company promoted Risperdal off-label to children. Two states previously won jury verdicts over the company’s marketing of the antipsychotic.

States Reap Rewards From Solo Suits Against Pharma; Atypical Antipsychotics May Offer Test Cases

First the federal government came knocking at their doors and then state attorneys general followed with claims of health care fraud. Now drug makers are dealing with another nemesis: states that file individual suits instead of joining multistate settlements.

Topics

UsernamePublicRestriction

Register

ID1135947

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel